Registry data—of sufficient quality—suitable for extended benefit assessment of drugs
Particularly in the case of accelerated drug approvals and drugs for rare diseases (orphan drugs), the evidence available at the time of market access is often insufficient for the early benefit assessment of drugs. Often, ...
Jan 24, 2020
0
1